AbbVie Inc. (NYSE:ABBV – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for AbbVie in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst C. Gould anticipates that the company will post earnings per share of $14.12 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $210.00 target price on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The business had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter last year, the firm earned $2.31 earnings per share. AbbVie’s quarterly revenue was up 8.4% on a year-over-year basis.
Get Our Latest Stock Analysis on ABBV
AbbVie Price Performance
Shares of NYSE ABBV opened at $191.27 on Tuesday. AbbVie has a twelve month low of $163.52 and a twelve month high of $218.66. The firm has a fifty day simple moving average of $183.78 and a 200 day simple moving average of $187.32. The company has a market capitalization of $337.86 billion, a PE ratio of 79.70, a P/E/G ratio of 1.62 and a beta of 0.50. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. eCIO Inc. acquired a new position in shares of AbbVie during the first quarter valued at about $182,000. Militia Capital Partners LP purchased a new position in AbbVie during the first quarter worth about $126,000. CBIZ Investment Advisory Services LLC boosted its holdings in AbbVie by 8.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 1,006 shares of the company’s stock worth $211,000 after purchasing an additional 79 shares during the last quarter. Invst LLC boosted its holdings in AbbVie by 68.9% during the first quarter. Invst LLC now owns 6,454 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,633 shares during the last quarter. Finally, Modern Wealth Management LLC boosted its holdings in AbbVie by 9.4% during the first quarter. Modern Wealth Management LLC now owns 52,808 shares of the company’s stock worth $11,064,000 after purchasing an additional 4,544 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of AbbVie stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This trade represents a 52.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.25% of the company’s stock.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More
- Five stocks we like better than AbbVie
- What Makes a Stock a Good Dividend Stock?
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- ESG Stocks, What Investors Should Know
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.